We can erase epigenetic insults to the genome and indeed the HDAC inhibitors vorinostat, romidepsin and belinostat have approval for treating some T-cell lymphoma patients and panobinostat for treating multiple myeloma patients. Here, HDAC9 is linked to T-cell non-Hodgkin lymphoma.